| Instrument studied (& version): SF-36 | | | | | | | |
|---------------------------------------|------------------|--|--------------------------|--------------------------------|----------------------------------|-------------------------------|-----------------------|
| Background and target use | | | | | | | |
| Target Domain: | Disease Activity | | | Dates & initial assessment | | | |
| • | | | | Working Group signoff: Review: | | | |
| Definition: | | | | Truth (domain match) | endorsed | start | end |
| | | | | Feasibility | endorsed | | 2019 |
| Target Population: | | Intervention(s): | | Control: | | Desired use: | |
| Patients with Psoriatic Arthritis | | drug/exercise | | standard/drug | | Clinical trials | |
| Review findings* | | | | | | | |
| Source | | Truth | | | Discrim | ination | |
| Author, ref | Year | Construct validity | Inter-method reliability | Test- retest reliability | Longitudinal construct validity† | Clinical trial discrimination | Thresholds of meaning |
| Husted | 1997 | + | | | | | |
| Husted | 1998 | | | | + | | |
| Taylor | 2007 | + | | | | | |
| Leung | 2008 | + | | | | | |
| Leung | 2010 | + | | | | | |
| Leung | 2011 | | | | ± | | ± |
| New data from Tillett | | | | + | | | |
| Kavanaugh | 2006 | | | | | | |
| Mease | 2017 | | | | | ± | |
| Gladman | 2017 | | | | | + | |
| Mease | 2018 | | | | | | |
| Synthesis | | | | | | | |
| Studies per property (n) | | 4 | | 1 | 2 | 4 | 1 |
| used in synthesis | | 4 | | 1 | 2 | 2 | 1 |
| Synthesis statement per property‡ | | GREEN | | AMBER | AMBER | AMBER | AMBER |
| OMERACT Endorsement¶ | | Based on these findings & the OMERACT algorithm, this instrument is: | | | | | |
| Date ratified: | | Provisionally Endorsed. | | | | | |